

Supplementary tables and figures

Table S1

Patient and tumor characteristics of the current study and the FLOT4-AIO trial

	This study		FLOT4-AIO trial	
Characteristics	Anthracyclin triplets (n= 913, %)	FLOT (n= 1069, %)	ECF/ECX (n= 360, %)	FLOT (n= 356, %)
Sex				
Male	597 (65)	733 (69)	265 (74)	268 (75)
Age (median [range])	66 (59 – 72)	67 (59 – 73)	62 (52 – 69)	62 (54 – 69)
Tumor type				
Adenocarcinoma	753 (83)	912 (85)	259 (72)	256 (72)
Signet ring cells	151 (17)	145 (14)	101 (28)	100 (28)
Other	9 (1)	12 (1)	-	-
Lauren classification				
Diffuse	363 (40)	381 (36)	96 (27)	95 (27)
Intestinal or mixed	395 (43)	579 (54)	163 (45)	159 (45)
Unknown	155 (17)	109 (10)	101 (28)	102 (29)
Clinical T-stage				
cT1	-	-	2 (1)	3 (1)
cT2	330 (36)	243 (23)	59 (16)	49 (14)
cT3	390 (43)	662 (62)	253 (70)	267 (75)
cT4a	46 (5)	85 (8)	33 (9)	28 (8)
cTx	147 (16)	79 (7)	13 (4)	9 (3)
Clinical N-stage				
cN0	480 (53)	529 (50)	70 (19)	77 (22)
cN+	404 (44)	507 (47)	290 (81)	279 (78)
Unknown	29 (3)	33 (3)	-	-
WHO performance status				
0	403 (44)	537 (50)	254 (71)	246 (69)
1	293 (32)	374 (35)	103 (29)	109 (31)
2	26 (3)	30 (3)	3 (1)	1 (<1)
3-4	2 (<1)	9 (1)	-	-
Unknown	189 (21)	119 (11)	-	-

FLOT: fluorouracil, leucovorin, oxaliplatin and docetaxel; ECF: epirubicin/cisplatin/5-fluorouracil; ECX: epirubicin/cisplatin/capecitabin

Table S2

Patient and tumor characteristics

Characteristics	Anthracyclin triplets (n= 913, %)	FLOT (n= 1069, %)	Primary resection (n= 1053, %)	P-value
Sex				
Male	597 (65.4)	733 (68.6)	656 (62.3)	0.010^a
Age (median [IQR])	66 (59 – 72)	67 (59 – 73)	78 (71 – 82)	N/A
Tumor type				
Adenocarcinoma	753 (82.5)	912 (85.3)	872 (82.8)	<0.001^a
Signet ring cells	151 (16.5)	145 (13.6)	144 (13.7)	
Other	9 (1.0)	12 (1.1)	37 (3.5)	
Differentiation grade				
Well differentiated (G1)	18 (2.0)	17 (1.6)	13 (1.2)	<0.001^a
Moderately differentiated (G2)	228 (25.0)	316 (29.6)	386 (36.7)	
Poorly differentiated (G3)	476 (52.1)	553 (51.7)	550 (52.2)	
Poorly differentiated (G3)	8 (0.9)	5 (0.5)	11 (1.0)	
Undifferentiated (G4)	183 (20.0)	178 (16.7)	93 (8.8)	
Grade cannot be assessed (Gx)				
Lauren classification				
Intestinal	360 (39.4)	529 (49.5)	573 (56.4)	<0.001^a
Diffuse	363 (39.8)	381 (35.6)	293 (28.8)	
Mixed	35 (3.8)	50 (4.7)	45 (4.4)	
Unknown	155 (17.0)	109 (10.2)	142 (13.5)	
Clinical T-stage				
cT2	330 (36.1)	243 (22.7)	370 (35.1)	<0.001^a
cT3	390 (42.7)	662 (61.9)	367 (34.9)	
cT4a	46 (5.0)	85 (8.0)	38 (3.6)	
cTx	147 (16.1)	79 (7.4)	278 (26.4)	
Clinical N-stage				
cN0	480 (52.6)	529 (49.5)	736 (69.9)	<0.001^a
cN1	249 (27.3)	326 (30.5)	193 (18.3)	
cN2	146 (16.0)	162 (15.2)	77 (7.3)	
cN3	9 (1.0)	19 (1.8)	2 (0.2)	
cN3a	-	-	1 (0.1)	
cNx	29 (3.2)	33 (3.1)	44 (4.2)	
WHO performance status				
0	403 (44.1)	537 (50.2)	246 (23.4)	<0.001^a
1	293 (32.1)	374 (35.0)	272 (25.8)	
2-4	28 (3.1)	39 (3.6)	147 (14.0)	
Unknown	189 (20.7)	119 (11.1)	388 (36.8)	
Number of comorbidities				
0	477 (52.2)	555 (51.9)	336 (31.9)	
1	347 (38.0)	437 (40.9)	361 (34.3)	
≥2	33 (3.6)	47 (4.4)	302 (28.7)	

Unknown	56 (6.1)	30 (2.8)	54 (5.1)	<0.001 ^a
---------	----------	----------	----------	-------------------------------

N/A: not applicable;

^a Chi-square p-value

Table S3

Number of patients who underwent primary resection over the past years

Year of treatment	Number of patients who underwent primary resection	Number of patients who underwent neoadjuvant therapy (\pm resection)	Total number of patients	Percentage of primary resections
2015	186	291	477	39.0%
2016	176	280	456	38.6%
2017	149	254	403	37.0%
2018	146	310	456	32.0%
2019	128	280	408	31.4%
2020	148	276	424	34.9%
2021	120	291	411	29.2%